Cymbalta Bottles Recalled; Suicides Highest on Mondays; New Dose of Pain Drug OK’d

Over 7,000 bottles of the antidepressant duloxetine (Cymbalta) were recalled due to the potential presence of a carcinogen. (USA Today)

Pretrauma psychosocial well-being may help protect against the development of post-traumatic stress disorder, researchers reported in JAMA Network Open.

In a study of 26 countries and territories, suicide risk was highest on Mondays and increased on New Year’s Day in most areas. (The BMJ)

Suicide-related emergencies are underdetected in minority youth and preteens, according to a review of electronic health record data. (JAMA Network Open)

Preliminary biomarker results of an ongoing phase II study of the investigational schizophrenia drug ANAVEX3-71 showed dose-dependent improvements in neural synchrony, thalamocortical circuits, and sensory gating, said Anavex Life Sciences.

The FDA approved oxycodone hydrochloride (Roxybond) immediate-release 10-mg tablets with abuse-deterrent technology for management of severe pain for which alternative treatments were inadequate, Protega Pharmaceuticals announced.

Could digital “avatars” be an effective treatment for psychosis? (STAT)

A Lancet Public Health Commission on gambling called for regulatory reform to tackle the health consequences of commercial gambling.

A panel will look into alleged incidents of abuse and neglect at the Psychiatric Institute of Washington. (Washington Post)

What happened to a U.S. study suggesting puberty blockers did not improve mental health in children with gender distress? (New York Times)

Please enable JavaScript to view the comments powered by Disqus.